Published in Proc Natl Acad Sci U S A on September 07, 2005
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog (2009) 5.82
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol (2012) 3.69
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A (2012) 3.33
Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov (2010) 2.69
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol (2013) 2.42
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol (2011) 2.34
Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci U S A (2008) 2.09
Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies (2005) 2.03
Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol (2010) 1.89
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines (2006) 1.88
Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A (2009) 1.87
The expanding horizons of asparagine-linked glycosylation. Biochemistry (2011) 1.82
Glycan microarrays for decoding the glycome. Annu Rev Biochem (2011) 1.81
Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog (2011) 1.70
Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog (2013) 1.65
Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells. J Clin Invest (2011) 1.54
Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells. PLoS Pathog (2015) 1.50
Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J Biol Chem (2012) 1.42
Very few substitutions in a germ line antibody are required to initiate significant domain exchange. J Virol (2010) 1.41
Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology (2010) 1.39
Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology (2010) 1.36
Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc Natl Acad Sci U S A (2014) 1.34
Carbohydrate microarray for profiling the antibodies interacting with Globo H tumor antigen. Proc Natl Acad Sci U S A (2005) 1.34
Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer. Proc Natl Acad Sci U S A (2008) 1.33
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses (2011) 1.30
Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J Virol (2011) 1.28
Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem Biol (2010) 1.21
A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN. J Virol (2009) 1.19
An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J Clin Invest (2014) 1.19
Multiple modes of binding enhance the affinity of DC-SIGN for high mannose N-linked glycans found on viral glycoproteins. J Biol Chem (2006) 1.17
An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions. Proc Natl Acad Sci U S A (2008) 1.15
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol (2012) 1.13
Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency. J Virol (2008) 1.11
A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc Natl Acad Sci U S A (2010) 1.10
Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains. Glycobiology (2009) 1.03
Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans. J Virol (2010) 1.01
Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. J Virol (2015) 1.00
Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing. PLoS One (2008) 0.99
Antibody WN1 222-5 mimics Toll-like receptor 4 binding in the recognition of LPS. Proc Natl Acad Sci U S A (2012) 0.99
Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. PLoS One (2012) 0.99
Dimeric 2G12 as a potent protection against HIV-1. PLoS Pathog (2010) 0.98
Synthetically defined glycoprotein vaccines: current status and future directions. Chem Sci (2013) 0.97
Antigenic properties of the HIV envelope on virions in solution. J Virol (2013) 0.97
Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J Virol (2011) 0.97
STD-NMR: application to transient interactions between biomolecules-a quantitative approach. Eur Biophys J (2011) 0.96
Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. J Biol Chem (2010) 0.95
Recent strategies targeting HIV glycans in vaccine design. Nat Chem Biol (2014) 0.94
Synthetic carbohydrate antigens for HIV vaccine design. Curr Opin Chem Biol (2013) 0.94
Directed evolution of multivalent glycopeptides tightly recognized by HIV antibody 2G12. J Am Chem Soc (2014) 0.91
Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. MAbs (2010) 0.91
Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. J Virol (2012) 0.90
Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc. Bioconjug Chem (2010) 0.90
The good and evil of complement activation in HIV-1 infection. Cell Mol Immunol (2010) 0.89
Synthesis of branched Man5 oligosaccharides and an unusual stereochemical observation. J Org Chem (2007) 0.88
Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope. J Mol Biol (2011) 0.87
HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity. PLoS One (2010) 0.87
The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry. J Biol Chem (2011) 0.87
A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. PLoS One (2013) 0.87
Directed evolution of 2G12-targeted nonamannose glycoclusters by SELMA. Chemistry (2013) 0.87
De novo asymmetric synthesis of all-D-, all-L-, and D-/L-oligosaccharides using atom-less protecting groups. J Am Chem Soc (2012) 0.86
A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120. FASEB J (2008) 0.86
High mannose-binding lectin with preference for the cluster of alpha1-2-mannose from the green alga Boodlea coacta is a potent entry inhibitor of HIV-1 and influenza viruses. J Biol Chem (2011) 0.86
Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1. J Biol Chem (2009) 0.85
Antibodies raised against chlamydial lipopolysaccharide antigens reveal convergence in germline gene usage and differential epitope recognition. Biochemistry (2010) 0.85
Preparation, characterization and immunogenicity of HIV-1 related high-mannose oligosaccharides-CRM197 glycoconjugates. Glycoconj J (2010) 0.84
Structural basis for enhanced HIV-1 neutralization by a dimeric immunoglobulin G form of the glycan-recognizing antibody 2G12. Cell Rep (2013) 0.84
Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA. Mol Pharm (2013) 0.82
Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies. Biochemistry (2009) 0.81
Microplate-based characterization of protein-phosphoinositide binding interactions using a synthetic biotinylated headgroup analogue. Bioconjug Chem (2009) 0.79
A strategy for phage display selection of functional domain-exchanged immunoglobulin scaffolds with high affinity for glycan targets. J Immunol Methods (2011) 0.79
The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development. AIDS (2013) 0.78
Thermal stability of the human immunodeficiency virus type 1 (HIV-1) receptors, CD4 and CXCR4, reconstituted in proteoliposomes. PLoS One (2010) 0.78
Global shape and ligand binding efficiency of the HIV-1-neutralizing antibodies differ from those of antibodies that cannot neutralize HIV-1. J Biol Chem (2014) 0.78
Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans. Vaccine (2015) 0.78
Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen. Bioeng Bugs (2011) 0.78
The ABRF MARG microarray survey 2005: taking the pulse of the microarray field. J Biomol Tech (2006) 0.77
Identification of Non-HIV Immunogens That Bind to Germline b12 Predecessors and Prime for Elicitation of Cross-clade Neutralizing HIV-1 Antibodies. PLoS One (2015) 0.77
Designing synthetic vaccines for HIV. Expert Rev Vaccines (2015) 0.77
Conference report: "Functional Glycomics in HIV Type 1 Vaccine Design" workshop report, Bethesda, Maryland, April 30-May 1, 2012. AIDS Res Hum Retroviruses (2013) 0.77
Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies. Glycobiology (2015) 0.77
Synthesis of a polymerizable, bivalent glycan mimetic of the HIV envelope spike gp120. Tetrahedron Lett (2015) 0.77
Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgM. Biochim Biophys Acta (2015) 0.76
Immunization with Outer Membrane Vesicles Displaying Designer Glycotopes Yields Class-Switched, Glycan-Specific Antibodies. Cell Chem Biol (2016) 0.76
High-throughput profiling of anti-glycan humoral responses to SIV vaccination and challenge. PLoS One (2013) 0.76
Antibody recognition of HIV and dengue glycoproteins. Glycobiology (2016) 0.75
Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose. Glycobiology (2014) 0.75
Interrogation of side chain biases for oligomannose recognition by antibody 2G12 via structure-guided phage display libraries. Bioorg Med Chem (2017) 0.75
Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. AIDS (2017) 0.75
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Raster3D: photorealistic molecular graphics. Methods Enzymol (1997) 27.30
Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr (2004) 23.86
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A (2004) 7.55
Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. Acta Crystallogr D Biol Crystallogr (1999) 6.87
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Diffraction methods for biological macromolecules. Interactive computer graphics: FRODO. Methods Enzymol (1985) 6.64
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11
The molecular surface package. J Mol Graph (1993) 4.24
Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med (2003) 2.79
Structure of myohemerythrin in the azidomet state at 1.7/1.3 A resolution. J Mol Biol (1987) 2.79
HIV vaccines 1983-2003. Nat Med (2003) 2.59
Oligosaccharide and glycoprotein microarrays as tools in HIV glycobiology; glycan-dependent gp120/protein interactions. Chem Biol (2004) 2.22
Synthesis of sugar arrays in microtiter plate. J Am Chem Soc (2002) 1.96
Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design. Chem Biol (2004) 1.53
Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody. Angew Chem Int Ed Engl (2004) 1.41
Covalent display of oligosaccharide arrays in microtiter plates. J Am Chem Soc (2004) 1.40
Probing protein-carbohydrate interactions with microarrays of synthetic oligosaccharides. Chembiochem (2004) 1.38
The chemistry of amine-azide interconversion: catalytic diazotransfer and regioselective azide reduction. J Am Chem Soc (2002) 1.38
Synthesis of the Globo H Hexasaccharide Using the Programmable Reactivity-Based One-Pot Strategy This research was supported by the National Institutes of Health. F.B. thanks the Deutsche Forschungsgemeinschaft for a fellowship. Angew Chem Int Ed Engl (2001) 1.17
Proteins that bind high-mannose sugars of the HIV envelope. Prog Biophys Mol Biol (2005) 1.14
In pursuit of carbohydrate-based HIV vaccines, part 2: The total synthesis of high-mannose-type gp120 fragments--evaluation of strategies directed to maximal convergence. Angew Chem Int Ed Engl (2004) 1.14
Toward fully synthetic carbohydrate-based HIV antigen design: on the critical role of bivalency. J Am Chem Soc (2004) 1.13
Reactivity-based one-pot total synthesis of fucose GM1 oligosaccharide: a sialylated antigenic epitope of small-cell lung cancer. Proc Natl Acad Sci U S A (2003) 1.12
Design and synthesis of a template-assembled oligomannose cluster as an epitope mimic for human HIV-neutralizing antibody 2G12. Org Biomol Chem (2004) 1.06
Reactivity-based one-pot synthesis of a Lewis Y carbohydrate hapten: a colon-rectal cancer antigen determinant. Angew Chem Int Ed Engl (2002) 1.02
In pursuit of carbohydrate-based HIV vaccines, part 1: The total synthesis of hybrid-type gp120 fragments. Angew Chem Int Ed Engl (2004) 0.99
Saccharide display on microtiter plates. Chem Biol (2002) 0.93
A new reactivity-based one-pot synthesis of N-acetyllactosamine oligomers. J Org Chem (2003) 0.91
Synthesis of monoglucosylated high-mannose-type dodecasaccharide, a putative ligand for molecular chaperone, calnexin, and calreticulin. J Am Chem Soc (2003) 0.91
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Antibody recognition of a highly conserved influenza virus epitope. Science (2009) 11.26
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science (2006) 10.04
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol (2006) 7.57
Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A (2004) 7.55
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science (2004) 6.70
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Recognition of bacterial glycosphingolipids by natural killer T cells. Nature (2005) 6.38
Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol (2005) 6.17
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11
Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science (2010) 6.10
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Structural genomics of the Thermotoga maritima proteome implemented in a high-throughput structure determination pipeline. Proc Natl Acad Sci U S A (2002) 6.00
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med (2009) 5.87
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog (2009) 5.82
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med (2005) 5.68
A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011) 5.66
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol (2006) 5.51
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol (2004) 5.29
GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol (2006) 5.28
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature (2008) 5.24
Toward an AIDS vaccine. Science (2008) 4.83
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog (2010) 4.47
Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med (2007) 4.47
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol (2008) 4.45
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science (2011) 4.42
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science (2007) 4.35
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog (2013) 4.23
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol (2006) 4.20
New world bats harbor diverse influenza A viruses. PLoS Pathog (2013) 4.10
Protein production and purification. Nat Methods (2008) 3.97
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013) 3.90
HIV vaccine research: the way forward. Science (2008) 3.86
Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science (2005) 3.72
Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol (2005) 3.70
Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A (2005) 3.57
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science (2012) 3.53
Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol (2011) 3.48
Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature (2008) 3.47
Highly conserved protective epitopes on influenza B viruses. Science (2012) 3.47
Exploration of uncharted regions of the protein universe. PLoS Biol (2009) 3.41
A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron (2002) 3.36
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35